180 related articles for article (PubMed ID: 15269926)
21. Thyroid vein thrombosis in a young woman with methylenetetrahydrofolate reductase gene mutation receiving cyproterone acetate/ethinylestradiol treatment for polycystic ovary syndrome: a case report.
Nazli Y; Colak N; Aksoy ON; Cakir O
Blood Coagul Fibrinolysis; 2011 Jun; 22(4):331-3. PubMed ID: 21415709
[TBL] [Abstract][Full Text] [Related]
22. The polycystic ovary syndrome presenting as resistant acne successfully treated with cyproterone acetate.
Eden JA
Med J Aust; 1991 Nov; 155(10):677-80. PubMed ID: 1834923
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate.
Vartiainen M; de Gezelle H; Broekmeulen CJ
Eur J Contracept Reprod Health Care; 2001 Mar; 6(1):46-53. PubMed ID: 11334476
[TBL] [Abstract][Full Text] [Related]
24. Venous thromboembolism and cyproterone acetate in men with prostate cancer: a study using the General Practice Research Database.
Seaman HE; Langley SE; Farmer RD; de Vries CS
BJU Int; 2007 Jun; 99(6):1398-403. PubMed ID: 17537215
[TBL] [Abstract][Full Text] [Related]
25. Diane-35 (cyproterone acetate): safety concerns.
Wooltorton E
CMAJ; 2003 Feb; 168(4):455-6. PubMed ID: 12591790
[No Abstract] [Full Text] [Related]
26. Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic and endocrine effects.
van Wayjen RG; van den Ende A
Exp Clin Endocrinol Diabetes; 1995; 103(4):241-51. PubMed ID: 7584530
[TBL] [Abstract][Full Text] [Related]
27. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives.
Farmer RD; Lawrenson RA; Todd JC; Williams TJ; MacRae KD; Tyrer F; Leydon GM
Br J Clin Pharmacol; 2000 Jun; 49(6):580-90. PubMed ID: 10848722
[TBL] [Abstract][Full Text] [Related]
28. Too much disclosure of product risks? CBC television, SOGC, and Diane-35.
Mintzes B; Lexchin J; Lippman A; Ford AR
J Obstet Gynaecol Can; 2003 Apr; 25(4):268-9; discussion 270-3. PubMed ID: 12679817
[No Abstract] [Full Text] [Related]
29. Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial.
Wang QY; Song Y; Huang W; Xiao L; Wang QS; Feng GM
Chin Med J (Engl); 2016 Apr; 129(8):883-90. PubMed ID: 27064030
[TBL] [Abstract][Full Text] [Related]
30. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
[TBL] [Abstract][Full Text] [Related]
31. Skin improvement with two different oestroprogestins in patients affected by acne and polycystic ovary syndrome: clinical and instrumental evaluation.
Colonna L; Pacifico V; Lello S; Sorge R; Raskovic D; Primavera G
J Eur Acad Dermatol Venereol; 2012 Nov; 26(11):1364-71. PubMed ID: 22011217
[TBL] [Abstract][Full Text] [Related]
32. First-use risks.
Rowe TC
CMAJ; 2003 May; 168(11):1394. PubMed ID: 12771065
[No Abstract] [Full Text] [Related]
33. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
[TBL] [Abstract][Full Text] [Related]
34. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Martínez-Bermejo E; Lasunción MA; Escobar-Morreale HF
J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
[TBL] [Abstract][Full Text] [Related]
35. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome.
Bhattacharya SM; Jha A
Fertil Steril; 2012 Oct; 98(4):1053-9. PubMed ID: 22795636
[TBL] [Abstract][Full Text] [Related]
36. [Oral contraceptives, risks and hazards].
Revuz J
Ann Dermatol Venereol; 2014 Jan; 141(1):5-6. PubMed ID: 24461087
[No Abstract] [Full Text] [Related]
37. Cyproterone acetate for severe hirsutism: results of a double-blind dose-ranging study.
Barth JH; Cherry CA; Wojnarowska F; Dawber RP
Clin Endocrinol (Oxf); 1991 Jul; 35(1):5-10. PubMed ID: 1832346
[TBL] [Abstract][Full Text] [Related]
38. Specific oral contraceptive use and venous thromboembolism resulting in hospital admission.
Heuser P; Tonga K; Hopkins R; Henderson M; Weatherall M; Metcalfe S; Beasley R
N Z Med J; 2004 Nov; 117(1206):U1176. PubMed ID: 15570345
[TBL] [Abstract][Full Text] [Related]
39. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism.
Venturoli S; Marescalchi O; Colombo FM; Macrelli S; Ravaioli B; Bagnoli A; Paradisi R; Flamigni C
J Clin Endocrinol Metab; 1999 Apr; 84(4):1304-10. PubMed ID: 10199771
[TBL] [Abstract][Full Text] [Related]
40. Effect of ethinyl estradiol-cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome.
Karakurt F; Carlioglu A; Kaygusuz I; Gumus II; Uz B; Akdeniz D
Arch Gynecol Obstet; 2014 Jan; 289(1):135-40. PubMed ID: 23880889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
